Hospira sued for patent infringement over allergic injections
Florida-based company Belcher Pharmaceuticals has filed a complaint against Hospira for patent infringement.
The case was filed on Friday, June 16, at the US District Court for the District of Delaware.
Belcher alleged that Hospira intends to market a generic epinephrine injection USP called Abboject.
The injection is used for emergency treatments of allergic reactions.
According to Belcher, Hospira’s plans to bring the injection to market infringe its US patent number 9,283,197, titled “More potent and less toxic formulations of epinephrine and methods of medical use”.
Belcher has asked the court for costs for bringing the case to court.
Today’s stories:
Section 101 raises fundamental question: 3M
Panellists tackle patent concerns after Brexit
FBI agent and lawyers provide trade secret tips
Industry at a crossroads over section 101
Pfizer and Takeda help to tackle Africa cancer crisis
Academic patents gave $1.3tn to US output
David Cameron talks Brexit, Trump and genomes
Google’s parent company invests $300m in biotech
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
